At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 233 enrolled
Drug / intervention
olodaterol (BI 1744) low +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, 8 Treatments, 4 Periods, Incomplete Crossover Study to Determine the Optimal Free Dose Combination of BI 1744 CL and Tiotropium Bromide (Both Delivered by the Respimat® Inhaler) After 4 Weeks Once Daily Treatment in Patients With COPD
In Brief
A Phase 2 clinical trial evaluating olodaterol (BI 1744) low, low tiotropium bromide, and 5 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 233 participants across 33 sites in 4 countries.
Detailed Summary
The primary objective of this study is to determine the optimum once daily dose of BI 1744 CL and tiotropium in free dose combination (delivered by the Respimat inhaler) after four week treatment in patients with COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesCanada, Germany, Netherlands, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartJan 2010
Primary CompletionFeb 2011
TodayJul 2026
First PostedDec 29, 2009
Enrollment StartJan 1, 2010
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.5 years ago
Interventions
olodaterol (BI 1744) lowdrug
olodaterol (BI 1744) low
low tiotropium bromidedrug
low tiotropium bromide
olodaterol (BI 1744) highdrug
olodaterol (BI 1744) high
medium tiotropium bromidedrug
medium tiotropium bromide
high tiotropium bromidedrug
high tiotropium bromide
Placebodrug
Placebo
Respimatdevice
Respimat inhaler